- Home
- NCTY vs PBYI Comparison
NCTY vs PBYI Comparison
Compare NCTY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- PBYI
- Stock Information
- Founded
- NCTY 1999
- PBYI 2010
- Country
- NCTY China
- PBYI United States
- Employees
- NCTY N/A
- PBYI N/A
- Industry
- NCTY Business Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- PBYI Health Care
- Exchange
- NCTY Nasdaq
- PBYI Nasdaq
- Market Cap
- NCTY 135.7M
- PBYI 153.2M
- IPO Year
- NCTY 2004
- PBYI N/A
- Fundamental
- Price
- NCTY $16.77
- PBYI $2.97
- Analyst Decision
- NCTY
- PBYI Strong Buy
- Analyst Count
- NCTY 0
- PBYI 1
- Target Price
- NCTY N/A
- PBYI $7.00
- AVG Volume (30 Days)
- NCTY 142.8K
- PBYI 821.3K
- Earning Date
- NCTY 01-01-0001
- PBYI 02-27-2025
- Dividend Yield
- NCTY N/A
- PBYI N/A
- EPS Growth
- NCTY N/A
- PBYI 492.79
- EPS
- NCTY 9.91
- PBYI 0.47
- Revenue
- NCTY $24,286,983.00
- PBYI $243,569,000.00
- Revenue This Year
- NCTY N/A
- PBYI N/A
- Revenue Next Year
- NCTY N/A
- PBYI N/A
- P/E Ratio
- NCTY $3.72
- PBYI $6.38
- Revenue Growth
- NCTY 2.82
- PBYI 6.30
- 52 Week Low
- NCTY $4.04
- PBYI $2.23
- 52 Week High
- NCTY $20.59
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- NCTY 59.29
- PBYI 45.95
- Support Level
- NCTY $13.68
- PBYI $2.92
- Resistance Level
- NCTY $16.56
- PBYI $4.06
- Average True Range (ATR)
- NCTY 1.24
- PBYI 0.27
- MACD
- NCTY -0.05
- PBYI -0.03
- Stochastic Oscillator
- NCTY 81.10
- PBYI 4.39
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China and other areas.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.